ANL 13.80 Decreased By ▼ -0.14 (-1%)
ASC 14.56 Increased By ▲ 0.86 (6.28%)
ASL 15.30 Increased By ▲ 0.04 (0.26%)
AVN 99.89 Increased By ▲ 0.29 (0.29%)
BOP 8.60 Decreased By ▼ -0.06 (-0.69%)
CNERGY 7.01 Decreased By ▼ -0.01 (-0.14%)
FFL 9.49 Increased By ▲ 0.10 (1.06%)
FNEL 9.39 Increased By ▲ 0.20 (2.18%)
GGGL 14.90 No Change ▼ 0.00 (0%)
GGL 22.12 Decreased By ▼ -0.47 (-2.08%)
GTECH 9.97 Decreased By ▼ -0.18 (-1.77%)
HUMNL 6.66 Decreased By ▼ -0.02 (-0.3%)
KEL 3.26 Decreased By ▼ -0.02 (-0.61%)
KOSM 4.38 Increased By ▲ 0.04 (0.92%)
MLCF 34.04 Increased By ▲ 0.14 (0.41%)
PACE 4.35 Increased By ▲ 0.02 (0.46%)
PIBTL 7.40 Decreased By ▼ -0.04 (-0.54%)
PRL 14.90 Increased By ▲ 0.14 (0.95%)
PTC 9.10 Decreased By ▼ -0.09 (-0.98%)
SILK 1.41 Decreased By ▼ -0.04 (-2.76%)
SNGP 34.50 Increased By ▲ 0.21 (0.61%)
TELE 17.75 Increased By ▲ 0.07 (0.4%)
TPL 15.35 Decreased By ▼ -0.24 (-1.54%)
TPLP 29.90 Increased By ▲ 0.15 (0.5%)
TREET 41.01 Increased By ▲ 0.21 (0.51%)
TRG 94.35 Decreased By ▼ -2.45 (-2.53%)
UNITY 28.20 Decreased By ▼ -0.49 (-1.71%)
WAVES 15.53 Decreased By ▼ -0.12 (-0.77%)
WTL 2.35 Decreased By ▼ -0.04 (-1.67%)
YOUW 8.22 Increased By ▲ 0.26 (3.27%)
BR100 4,678 Decreased By -8.6 (-0.18%)
BR30 18,623 Decreased By -17.3 (-0.09%)
KSE100 45,507 Decreased By -104.8 (-0.23%)
KSE30 17,926 Decreased By -16.4 (-0.09%)

coronavirus
Coronavirus
VERY HIGH
Source: covid.gov.pk
Pakistan Deaths
29,029
1024hr
Pakistan Cases
1,333,521
5,03424hr
Sindh
505,930
Punjab
454,372
Balochistan
33,729
Islamabad
111,855
KPK
182,419
Business & Finance

Sanofi, GSK say Covid vaccine shows positive result

  • "Our Phase 2 data confirm the potential of this vaccine to play a role in addressing this ongoing global public health crisis," said Thomas Triomphe, executive vice president and global head of Sanofi Pasteur.
Updated 17 May, 2021

PARIS: French pharmaceuticals giant Sanofi and Britain's GSK reported on Monday "strong immune responses" in early tests of their Covid-19 vaccine, raising hopes it could join the fight against the pandemic.

The companies said the results of the Phase 2 study will enable them to move to a late-stage trial in the coming weeks -- a reversal of fortune after their research was dealt a setback late last year.

The experimental vaccine "achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a Phase 2 study with 722 volunteers," it said in a statement.

"A global pivotal Phase 3 study is expected to start in the coming weeks."

An earlier study in late 2020 showed the vaccine provided a low immune response in older adults. The companies said the vaccine would not be ready until the end of 2021.

The initial failure was a setback that dented French pride as France is the only permanent member of the UN Security Council not to have its own vaccine after successes for Britain, China, Russia and the United States.

"Our Phase 2 data confirm the potential of this vaccine to play a role in addressing this ongoing global public health crisis," said Thomas Triomphe, executive vice president and global head of Sanofi Pasteur.

"As we know multiple vaccines will be needed, especially as variants continue to emerge and the need for effective and booster vaccines, which can be stored at normal temperatures, increases," he said.

The firms are combining a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK's adjuvant technology, a substance that bolsters the immune response triggered by a vaccine.

Comments

Comments are closed.